Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT05940363 Not yet recruiting - Prenatal Diagnosis Clinical Trials

The National Program for the Improvement of Management of Fetal Congenital Heart Disease in China

Start date: July 1, 2023
Phase:
Study type: Observational [Patient Registry]

To investigate and evaluate the capacity of prenatal screening, diagnosis and counseling of congenital heart disease in medical institutions in China, in order to understand the current status and existing problems of prenatal prevention and treatment capacity of congenital heart disease in China, and to obtain corresponding baseline data, so as to provide scientific basis for further improving prenatal screening and diagnosis policies in China.

NCT ID: NCT05938491 Not yet recruiting - Clinical trials for Proliferative Diabetic Retinopathy

OCT and OCT-A Afer Diabetic Vitrectomy in PDR

Start date: August 1, 2023
Phase:
Study type: Observational

Detection of any structural or vascular changes at the macula after Pars Plana Vitrectomy ( PPV ) in cases with complicated proliferative diabetic retinopathy ( PDR )

NCT ID: NCT05938036 Not yet recruiting - Clinical trials for Acute Respiratory Distress Syndrome (ARDS)

Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS

Start date: January 14, 2024
Phase: Phase 2
Study type: Interventional

A Phase 2a, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of ALT-100mAb in patients with moderate to severe ARDS.

NCT ID: NCT05937412 Not yet recruiting - Clinical trials for Disinfectant Causing Toxic Effect

A Comparative Study Between Honey and Alcohol as Topical Skin Disinfectant

Start date: August 30, 2023
Phase: N/A
Study type: Interventional

Skin antisepsis is essential in every healthcare environment. Alcohol/chlorhexidine use might disrupt skin microbiota and lead to antibiotic resistance. This study investigates honey (being natural product with many beneficial therapeutic effects) as topical skin anti-septic agent and compares it with alcohol, in terms of effectiveness and safety.

NCT ID: NCT05936229 Not yet recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Start date: April 1, 2025
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial tests the safety and how well intravenous interferon-beta-1a (FP-1201) works in preventing toxicities after CD19-directed chimeric antigen receptor (CAR) T-cell therapy in patients with B-cell cancers that has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory). Interferon beta-1a is in a class of medications called immunomodulators. It works by protecting the lining of blood vessels, and preventing brain inflammation. Giving FP-1201 may prevent cytokine release syndrome (CRS) and immune effector cell associated-neurotoxicity syndrome (ICANS) toxicities in patients receiving CD19 CAR T-cell therapy with recurrent or refractory B-cell malignancies.

NCT ID: NCT05936112 Not yet recruiting - Clinical trials for Functional Gastrointestinal Disorders

Quantification of Fecal Calprotectin Concentration Difference Between Infants Aged Under 4 Months Old Suffering From Functional Gastrointestinal Disorders (FGID) and Infants Aged Under 4 Months Old Free From Disorders : a Transversal Case-control Monocentric Study

Cal-IBS
Start date: September 2023
Phase: N/A
Study type: Interventional

There is a high prevalence of FGID among infants : 30 % for regurgitations, 20 % for colitis , 15 % for functional constipation.This represents a frequent motive for pediatrics consultation : 23 to 28 % of medical consultations in this population are consequent to gastrointestinal symptoms among infants aged under 4 months old. This can lead to numerous inappropriate or unrecommended medication prescriptions. Currently, fecal calprotectin threshold are only validated by science societies for children aged 5 years old and more. This study aims to quantify the difference of fecal calprotectin between a population of infants for whom no FGID has been finally detected, and a population of infants for whom FGID have been detected during the gastro-pediatrics consultation, , in order to later determine wether it is possible to validate a threshold in a population of infants aged under 4 months old.

NCT ID: NCT05935423 Not yet recruiting - Clinical trials for ST Elevation Myocardial Infarction

Umbilical Cord Mesenchymal Stem Cell Improve Cardiac Function on ST-elevation Myocardial Infarction (STEMI) Patients

Start date: July 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to learn about the effectiveness of Umbilical Cord Mesenchymal Stem Cell (UC MSC) therapy in patients with STEMI against infarct myocardial size reduction and prevent the incidence of heart failure in the future

NCT ID: NCT05934929 Not yet recruiting - Clinical trials for Squamous Cell Carcinoma of the Oral Cavity

Contribution of Residual Tumour DNA Testing on the Surgical Bed

MARGINS
Start date: August 1, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the interest of residual tumour DNA research in the operating bed after squamous cell carcinoma excision.

NCT ID: NCT05934643 Not yet recruiting - Clinical trials for Colorectal (Colon or Rectal) Cancer

An Observational Cohort Study to Assess the Postop Activity of Colorectal Patients Undergoing Elective Surgery (PHYSPAL)

PHYSPAL
Start date: September 1, 2023
Phase:
Study type: Observational

All participants will have a physical activity monitor placed onto the right thigh in the midline which will start collecting data at midnight on the first postoperative day. This will continue until discharge or day 7, whichever is earlier. This is a non-invasive measure of activity and can discriminate between whether a patient is lying, sitting, standing or walking. There is no control group.

NCT ID: NCT05934084 Not yet recruiting - Clinical trials for Classical Hodgkin Lymphoma

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This is a prospective randomized open-label, multicenter, 2-arm study to assess the role of healthy LifeStyle implemented Survivorship Care Plan (LS-SCP) in modifying the Quality of Life (QoL) in a population of long-term lymphoma survivors (in remission for a minimum 3 years since the last treatment and a maximum of 10 years).